# US 2013/0096116 A1 · Treatment of pharmacological-induced hypochlorhydria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0096116 A1
- Document ID: US20130096116A1
- Status: Published application
- Kind: A1
- Application number: 13/650,274
- Filed: 2012-10-12
- Published: 2013-04-18
- Earliest claimed: 2011-10-13
- Assignees: Genentech, Inc.
- Inventors: Gena Dalziel; Brian James Dean; Mark Jason Dresser; Adam Frymoyer; Scott Naylor Holden; Jin Yan Jin; Joseph Alan Ware; Leslie Z. Benet
- Web page: https://patentgrep.com/patent/US20130096116A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Changes in gastric pH due to oral co-administration of acid-reducing agents, such as proton pump inhibitors, and oncology drugs can have a marked impact on the absorption and oral bioavailability of the oncology drug if the pH decreases the maximal absorbable dose. Moreover, there is a potential for specific drug-drug interactions between some of the acid-reducing agents and these drugs. Methods are described for treating patients on gastric acid-reducing therapy with orally-administered PI3K inhibitor compound GDC-0941. Treatment with a re-acidification compound during treatment with GDC-0941 improves bioavailability of GDC-0941.

## Claims

### Claim 1

A method of treating a hyperproliferative disorder comprising administering a re-acidification compound and GDC-0941 having the formula:
to a patient receiving a gastric acid-reducing therapeutic selected from a proton-pump inhibitor, an H2-receptor antagonist, and an antacid.

### Claim 2 (depends on 1)

The method of claim 1 wherein the re-acidification compound is selected from betaine hydrochloride and glutamic acid hydrochloride.

### Claim 3 (depends on 1)

The method of claim 1 wherein the proton-pump inhibitor is selected from omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole.

### Claim 4 (depends on 1)

The method of claim 1 further comprising determining the gastrin level or the GDC-0941 concentration of a sample from the patient.

### Claim 5 (depends on 1)

The method of claim 1 wherein the patient has a hyperproliferative disorder.

### Claim 6 (depends on 1)

The method of claim 1 wherein the hyperproliferative disorder is a solid tumor or a hematological malignancy.

### Claim 7 (depends on 1)

The method of claim 1 wherein the bioavailability of GDC-0941 in the patient is higher than when GDC-0941 and the gastric acid-reducing therapeutic are administered without the re-acidification compound.

### Claim 8 (depends on 1)

The method of claim 1 wherein the pH of the gastric juices in the patient is lower than when GDC-0941 and the gastric acid-reducing therapeutic is administered without the re-acidification compound.

### Claim 9 (depends on 1)

The method of claim 1 wherein GDC-0941 and the re-acidification compound is formulated in an oral dosage form.

### Claim 10

A method of increasing the bioavailability of GDC-0941, having the formula:
comprising coadministering to a patient receiving a gastric acid-reducing therapeutic agent, an effective amount of a re-acidification compound effective to enhance the bioavailability of GDC-0941.
